Key result
PFO closure yields an absolute ~3% reduction in 5-year recurrent stroke risk vs medical therapy.
Why the study?
To establish catheter-based patent foramen ovale (PFO) closure as a safe and effective treatment in clinical practice, the accuracy of PFO diagnosis and long-term safety require confirmation.
Does transcatheter closure of patent foramen ovale reduce the risk of recurrent stroke compared with conventional antithrombotic therapy in patients with cryptogenic stroke?
Does transcatheter closure of patent foramen ovale reduce the risk of recurrent stroke compared with conventional antithrombotic therapy in patients with cryptogenic stroke?
Answers are grounded in this paper and cite their sources.
This review summarizes evidence supporting transcatheter PFO closure for secondary stroke prevention in young cryptogenic stroke patients and defines five echocardiographic criteria for identifying 'high-risk PFO' morphology.
Recent prospective controlled studies have demonstrated that transcatheter closure of a patent foramen ovale (PFO) reduces recurrent stroke risk in select patients, especially in patients younger than 60 years with PFO and embolic-appearing infarct and where no other mechanism of stroke was identified. Detection of PFO depends on the intensity of the Valsalva maneuver, and not all PFOs can be diagnosed using transesophageal echocardiography. Transthoracic contrast echocardiography using abdominal compression during the Valsalva maneuver is an easy method that can increase the detection sensitivity of PFO shunt. PFO with two or more of the following factors is most likely considered a "high-risk PFO" and as such, has a significantly higher probability of cryptogenic stroke: (1) a long-tunnel PFO (≥10 mm in length), (2) atrial septal aneurysm and/or hypermobile interatrial septum, (3) prominent Eustachian valve or Chiari's network, (4) large right-to-left shunt at rest and during the Valsalva maneuver, and (5) low-angle PFO. In order to establish the benefit of catheter-based PFO closure as a safe and effective treatment in clinical practice, the degree of accuracy of PFO diagnosis and its long-term safety need to be confirmed.
No takes yet. Share an insight, caveat, or question.
Teiji Akagi (2020) conducted a review in Patent foramen ovale (PFO) and cryptogenic stroke / paradoxical cerebral embolism. Transcatheter closure of patent foramen ovale (PFO) vs. Conventional antithrombotic therapy (antiplatelet or anticoagulant therapy) alone was evaluated on Recurrent stroke risk (ARR 3.4% at 5 years). Transcatheter PFO closure reduces recurrent stroke risk in select patients <60 years with cryptogenic stroke compared to medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: